Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) has issued an update.
JCR Pharmaceuticals has released materials for its FY2025 third-quarter results briefing, outlining its financial performance and progress in business operations. The company emphasizes that any forecasts or projections in the briefing are subject to significant uncertainties and risks, and that actual results may differ materially from these forward-looking statements, underscoring a cautious stance for investors and other stakeholders when interpreting its outlook.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen705.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange Prime Market (securities code 4552), focusing on the development and commercialization of pharmaceuticals and medical devices, including products under development that are often aimed at addressing rare diseases and specialized medical needs.
Average Trading Volume: 975,166
Technical Sentiment Signal: Hold
Current Market Cap: Yen83.9B
For a thorough assessment of 4552 stock, go to TipRanks’ Stock Analysis page.